Latest Headlines

Online Exclusive

Quality of Generic Drugs Manufactured Overseas Comes into Question

The passage of the Hatch-Waxman Act in 1984, which created a regulatory track for generic drugs, marked the beginning of the generic-drug boom in...

Who Foots the Surprise Bill?

As U.S. Senators prepare for a July vote on proposed legislation that would protect patients from surprise medical bills, three key players in the...

Cover Story

Predatory Publishing: The Dark Side of the Open-Access Movement

In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker side of scientific publishing: predatory publishing. This segment of the OA publishing movement is characterized by publishers that “unprofessionally exploit” the gold OA model (in which the final version of a manuscript is made freely available on publication), primarily for profit, according to Jeffrey Beall, MSLS, one of the most vigilant watchdogs of predatory publishing, and operator of the website Scholarly Open Access. Sometimes called “vanity presses,” these entities publish practically any materials that come their way, as long as authors are willing to pay a submission and publication fee. Critics – and they are legion...

Clinical News

Latest Videos

Pulling Back the Curtain: Lukas Wartman, MD

In more from our interview with Lukas Wartman, MD, he discusses his decision to go into medicine and his life as a doctor and...

Pulling Back the Curtain: Dan Pollyea, MD, MS

In more from our interview with Dan Pollyea, MD, MS, he shares what he learned from growing up watching his father practice medicine and the simple...

Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism

Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...

Ravulizumab: A New Treatment Option for PNH?

Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

On Location

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS)...

Are CAR T-Cell Therapies Moving to Hodgkin Lymphoma?

Results from two studies presented at the 2019 Transplantation & Cellular Therapy Meetings suggest that...

RADIUS: Midostaurin Reduces Post-Transplant Relapse Risk in FLT3-Mutated AML

Post-transplant maintenance therapy with midostaurin was safe and reduced relapse risk in patients with FLT3-mutated...

Post-Transplant Ixazomib Maintenance Prolongs Survival in Newly Diagnosed Myeloma

For patients with newly diagnosed multiple myeloma (MM) who relapse following autologous hematopoietic cell transplantation...

Adoptive “Non-Engineered” T-Cell Therapy Shows Preliminary Efficacy in Lymphomas

Chimeric antigen receptor (CAR) T-cell therapies engineered to recognize and destroy CD19 antigens on the...

Beta-Thalassemia Gene Therapy Continues to Show Efficacy in Longer-Term Follow-up

Updated results from the phase I/II HGB-204 and HGB-207 trials indicated that several patients with...
Advertisement

Sign Up for our enewsletter!

Subscribe to our newsletter to receive the latest news, updates and online exclusive content.

8,802FollowersFollow
8,855SubscribersSubscribe

Quality of Generic Drugs Manufactured Overseas Comes into Question

The passage of the Hatch-Waxman Act in 1984, which created a regulatory track for generic drugs, marked the beginning of the generic-drug boom in...

Who Foots the Surprise Bill?

As U.S. Senators prepare for a July vote on proposed legislation that would protect patients from surprise medical bills, three key players in the...

More Than 40 States File Suit Against Generic Drug Manufacturers

Forty-three states and Puerto Rico have filed a lawsuit against 20 of the largest U.S. generic drug manufacturers. They allege that the companies manipulated...

Benchmarking Drug Prices Could Save the U.S. Billions on Medicare Part D

The U.S. could save billions by pegging drug prices to what other countries pay, according to a new study in Health Affairs. The research indicates...

Coming Soon to a TV Near You: List Prices for Drugs

Television advertisements for prescription drugs will soon need to include list prices, according to new regulations from the U.S. Department of Health and Human...